Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.44 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.44 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.43 |
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 0.41 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.41 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953627 | 0.95 | KMT2A (0.47) | KMT2AGAAALDH1A1MEN1CA1 | |
| Potassium Ion SCHEMBL25178937 | 0.95 | KMT2A (0.47) | KMT2AGAAALDH1A1MEN1CA1 | |
| SCHEMBL10858807 | 0.88 | MAPT (0.39) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL5001127 | 0.80 | ENPP2 (0.46) | CA2 | |
| SCHEMBL4400952 | 0.78 | KMT2A (0.62) | KMT2AGAAALDH1A1MEN1CA1 | |
| SCHEMBL9820117 | 0.77 | ALDH1A1 (0.59) | KMT2AGAAALDH1A1MEN1CYP3A4 | |
| SCHEMBL28924124 | 0.77 | LMNA (0.44) | CA1CA2CA9CA12ESR1 | |
| SCHEMBL30876382 | 0.77 | FFAR4 (0.35) | GAAALDH1A1CA1CA2CA9 | |
| SCHEMBL9000871 | 0.77 | PLCG1 (0.46) | CA1CA2CA9CYP3A4CYP2C9 | |
| SCHEMBL4860076 | 0.77 | CA1 (0.39) | CA1CA2CA9CYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778197-A | Preparation method of novel abscisic acid agonist AM1 | 邵阳学院 | 2021-05-11 | — | — | CN | claimed |
| US-11535647-B2 | Peptide purification method using sulfonate compound | NAGASE & CO., LTD. (JP) | 2022-12-27 | — | — | US | disclosed |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | NAGASE & CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| CN-112533936-B | Method for purifying peptide using sulfonic acid compound | 长濑产业株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-112533936-A | Method for purifying peptide using sulfonic acid compound | 长濑产业株式会社 | 2021-03-19 | — | — | CN | disclosed |
| EP-1045836-B1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1171113-A1 | COMPOUNDS USEFUL AS PHOSPHOTYROSINE MIMICS | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6284768-B1 | Src family SH2 domain inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| US-6268365-B1 | Src family SH2 domain inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-07-31 | — | — | US | disclosed |
| US-6156784-A | Compounds useful as phosphotyrosine mimics | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| WO-2000062770-A1 | COMPOUNDS USEFUL AS PHOSPHOTYROSINE MIMICS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1045836-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-6054470-A | Src family SH2 domain inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999031066-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-4159979-A | P-METHYLBENZYLSULFONYL GROUP FOR AMINO GROUPS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-07-03 | — | — | US | disclosed |
| US-4150049-A | P-NITROPHENYL AMIDINOPHENYLMETHANESULFONATE, THROMBIN INACTIVATION | THE GOVERNMENT OF THE UNITED STATES (US) | 1979-04-17 | — | — | US | disclosed |
| US-4001087-A | INACTIVATION OF THROMBIN | THE UNITED STATES OF AMERICA (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | VIP, IAPP, RPS27A | CA1 331/4885CA2 1327/4885CA12 287/4885 |
| US-11535647-B2 | Peptide purification method using sulfonate compound | VIP, IAPP, RPS27A | CA1 331/4885CA2 1327/4885CA12 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.